Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02718001 · ClinicalTrials.gov registry record · NA
Edwards EVOQUE Eos MISCEND Study
A NA study of Mitral Valve Regurgitation (Degenerative or Functional), sponsored by Edwards Lifesciences.
- Active
- Registry status
- NA
- Development phase
- 123
- Enrollment target
- 19
- Study locations
NCT02718001: Active NA study of Mitral Valve Regurgitation (Degenerative or Functional), sponsored by Edwards Lifesciences.
NCT02718001 is a NA study of Mitral Valve Regurgitation (Degenerative or Functional) that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 123 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02718001, a NA study of Mitral Valve Regurgitation (Degenerative or Functional), is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 123 participants
- Enrollment target
- 19
- Study locations
Study Summary
Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
Primary Outcome
Proportion of patients with major adverse events
Conditions Studied
Interventions
- DEVICE Edwards EVOQUE Eos Mitral Valve Replacement System
Study Locations (19)
California
- Sutter Mills-Peninsula - Burlingame
- Cedars-Sinai Medical Center - Los Angeles
- Kaiser Permanente San Francisco - San Francisco
Texas
- The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center - Houston
- The Heart Hospital Baylor Plano - Plano
Other
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval - Québec
- St. Michael's Hospital - Toronto
Georgia
- Emory University Hospital/Emory University Hospital Midtown - Atlanta
Illinois
- Northwestern University - Chicago
Indiana
- St. Vincent Heart Center - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Morristown Medical Center - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2015-02-06 |
| Est. Completion | 2033-04-30 |
| Phase | NA |
What the registry record for NCT02718001 still lists
NCT02718001 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Mitral Valve Regurgitation (Degenerative or Functional) appearing as the primary indexed condition, and to 1 intervention - of which Edwards EVOQUE Eos Mitral Valve Replacement System is the first listed.
NCT02718001 lists 19 locations in 15 states (California, Texas, Other).
Frequently Asked Questions
What is clinical trial NCT02718001 about?
NCT02718001 is a clinical study titled "Edwards EVOQUE Eos MISCEND Study". Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
What is the current status of trial NCT02718001?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 123 participants. The study started on 2015-02-06. Estimated completion is 2033-04-30.
What conditions does trial NCT02718001 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation (Degenerative or Functional).
What interventions are being tested in trial NCT02718001?
The interventions under investigation include: Edwards EVOQUE Eos Mitral Valve Replacement System (DEVICE).
Who is sponsoring clinical trial NCT02718001?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02718001 being conducted?
This trial has 19 study locations across California, Georgia, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Valve Regurgitation (Degenerative or Functional)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02718001's enrollment target sits among peer trials
123 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI